Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. - Wikidata - awgldk - TriplyDB

Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

http://www.wikidata.org/entity/Q35497877

about

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia Fibroblast growth factor 23 Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature FGF23 and Phosphate Wasting Disorders Fibrous dysplasia and fibroblast growth factor-23 regulation Fibroblast growth factor (Fgf) 23 gene transcription depends on actin cytoskeleton reorganization.Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.The changing face of hypophosphatemic disorders in the FGF-23 era β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin.Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.Fibroblast growth factor 23 and acute kidney injury.Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models.Iron status and fibroblast growth factor-23 in Gambian children.Update on fibroblast growth factor 23 in chronic kidney disease.Vitamin D status is inversely associated with anemia and serum erythropoietin during pregnancy.FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.Fibroblast growth factor 23: state of the field and future directions FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study.The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism.Genome-wide association study of serum iron phenotypes in premenopausal women of European descent.Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women.High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.Systemic Control of Bone Homeostasis by FGF23 Signaling.Insights from genetic disorders of phosphate homeostasis What's new in FGF23 research?Inflammation regulates fibroblast growth factor 23 production.Autosomal dominant hypophosphatemic rickets in an 85 year old woman: characterization of her disease from infancy through adulthood.Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children.Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia

P2860

Q26750413-F71CEFE8-BB9B-430A-8746-2D7D872FB11A Q26829294-46C94B3C-41C4-4FC2-96B6-3ED4184C21FE Q26830906-099B2B30-70FB-44D1-881B-27D8EE22712B Q26851904-3F40A6D2-1448-4517-BF03-0C7DADDFCAD0 Q27010789-0E88AFE9-5D22-484D-AFB6-770FE6DB68B9 Q30315564-F299A172-C957-47BD-B307-8AE905AED991 Q30316351-C0F84A3D-E84E-4C5B-8F49-E84156C37071 Q33643233-0A35098B-D084-4925-B3F2-E76676538D89 Q33904467-31436C81-3F2D-42EC-B630-65B88587C9C4 Q34069793-C43C051A-8DC5-4E98-9C07-7073DA69A144 Q34185739-FC043A83-DE3B-461A-BA64-178D85ACDBE6 Q34221238-B6C9BF47-DE8F-48EF-A2B0-7F87954A0F93 Q34612398-8BBED234-CDB2-40BF-BBF4-4839C7A08859 Q34650666-E4113EC8-C291-4B8F-959E-62A42A2D972B Q34884492-F9FB7F07-7B71-441B-A7CD-6EADF11EEBCB Q35067500-2E276D89-B7DA-4D4A-927E-785A275EC226 Q35077013-0287923F-CEAC-4702-A3DC-B5713DEF9011 Q35140676-98F606C1-5D32-4940-B1B6-B6AF5C466F08 Q35558693-35B12B17-7835-4260-BE01-CD8AAC84E245 Q35690579-36CBED31-E987-4E85-B910-5D0AEAF4E3F4 Q35755137-A3FCEED5-035E-4837-83CB-A558C5B204B8 Q35987934-C28CF1B9-4F93-46CE-A446-B17BDF2C7FF4 Q36210285-C7A54E3C-B27C-4D5A-8CDA-BF6EA60AE687 Q36223069-22C374AF-A1C4-4A9C-B670-A1C8BF027842 Q36260612-C9CFF54D-FC22-47F4-ADA9-41312F757848 Q36413230-99897C26-F26A-4E2B-AF26-7EBD0B76E6A8 Q36468751-8577857F-C0FA-43B7-A8B5-1BFCF4E0578D Q36482983-D5394638-EB3C-4025-8B8B-2D016A0EFA8C Q36559715-FB017CAF-2797-42BD-A4AF-324B9CD68897 Q36614486-9527CEBA-96F7-45DB-8971-A41D11A3C8D8 Q36820702-3D0298CA-7E1B-4D1D-817E-AD33ED9D1021 Q36822751-9ED0EC23-3325-41BC-B810-D0191A694D12 Q36843642-D1F1D528-2F2F-469E-9915-4E965FF58327 Q36911899-D5658501-8D73-48EA-A35F-C2B692D7A534 Q37056389-5B770DB6-1019-4035-B160-6FF3D0E660BA Q37243107-DB168AB4-DF55-445E-9363-BBAFF59B4469 Q37406152-16A15376-7D62-45E5-B6D6-1311CD342644 Q37407740-61E7668A-8B13-4D8E-9AA1-E5B0F75DDC0F Q37592511-F06FEAD3-E03D-40CB-9279-4808EFCFB17F Q37629734-E2951439-1FE4-4E29-8C24-A5D9D1D96D2F

P2860

Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

http://www.wikidata.org/entity/Q35497877

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@ast

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@en

type

label

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@ast

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@en

prefLabel

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@ast

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@en

P1433

Q35497877-3347ADE4-EB39-4170-9306-2D8FD9489EDF

P1476

Q35497877-08B439EA-DE13-4BFF-99D1-60C7EF2C318E

P2093

Q35497877-2A31887C-4F9A-48CE-8C61-C20A9B7749A3

Q35497877-434BB1CC-0B29-4397-B9D7-84050FE1C91A

Q35497877-F8E451C8-F406-421F-A29D-F6CF6A334087

Q35497877-F9E31321-7DA9-4CDA-9BFD-7A8486767C9F

P2860

Q35497877-023FD96C-4189-4E34-990F-EDB75B024679

Q35497877-0633D74B-9BD9-4BE0-B6D6-BD5AEA20D1AA

Q35497877-2957F2B3-FDF9-4EB4-8C86-8F84FFF1BBFC

Q35497877-4657F4FE-3106-4E2E-8195-EFCC2953B248

Q35497877-6D60DB52-DD4E-4B9A-9EA3-D121354DEAD1

Q35497877-81D6370D-178F-4500-964F-49A3B53A73D9

Q35497877-9505B9EE-2012-4B42-82BC-9DD5BF08D723

Q35497877-B32E3EFE-01B9-40D6-8BAC-76DB1974E645

Q35497877-BC92D064-097E-4A8F-8FAA-75FE71E2F0B3

Q35497877-C28D1800-57E6-41A1-BC51-76CC1162759F

P304

Q35497877-A764B619-0894-493A-91D1-9A5A9DC822EC

P31

Q35497877-69DBA03C-498A-4D02-85C0-C7C30F26513D

P356

Q35497877-3230199B-8E62-40A7-96DB-0DB7E987BCBC

P407

Q35497877-6060A656-2957-48B6-A267-244AAE76CAA9

P433

Q35497877-6E35BC6C-8751-4669-B485-14A65284A755

P478

Q35497877-A0729E91-DAB3-4C3A-9927-5CD3F7EA942C

P50

Q35497877-4F35D45D-BC02-4D5E-A10F-03C66516EA2C

Q35497877-84DBC460-7619-4BEC-A210-77A6E14FB6EA

P577

Q35497877-678D6ABA-E065-4825-A0C5-F20BC4910E87

P698

Q35497877-2FB7D123-BD1C-4276-B0F6-2BCEF5826DE1

P921

Q35497877-908EB3C1-DE21-4AA4-B2CB-5DDC9EF16EC8

P932

Q35497877-DF76ED29-DE93-4EA0-8817-B9BCE1C794F5

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Iron modifies plasma FGF23 dif ...... ic rickets and healthy humans.

@en

P2093

Amie K Gray

http://www.w3.org/2001/XMLSchema#string

Leah R Padgett

http://www.w3.org/2001/XMLSchema#string

Munro Peacock

http://www.w3.org/2001/XMLSchema#string

Siu L Hui

http://www.w3.org/2001/XMLSchema#string

P2860

Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

Genome-wide association study of bone mineral density in premenopausal European-American women and replication in African-American women

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23

An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation.

Excess iron inhibits osteoblast metabolism.

FGF23 is processed by proprotein convertases but not by PHEX.

FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice.

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

P304

3541-3549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2011-1239

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Michael J Econs

P577

2011-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21880793

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant hypophosphatemic rickets

P932

3205884

http://www.w3.org/2001/XMLSchema#string